カテゴリ： Allied Market Research, 世界, 医療/バイオ

関節痛注射のグローバル市場（2021〜2031）：インターロイキン阻害剤、ヒアルロン酸注射、その他

■ 英語タイトル：Joint Pain Injections Market By Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections, Others), By Joint Type (Knee and Ankle, Hip Joint, Shoulder and Elbow, Facet Joints of the Spine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB180）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB180
■ 発行日：2022年11月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：310
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[関節痛注射のグローバル市場（2021〜2031）：インターロイキン阻害剤、ヒアルロン酸注射、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に6,271.91百万ドルであった世界の関節痛注射市場規模が、2031年までに13,176.31百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）7.7%で成長すると予測しています。本レポートは、関節痛注射の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、注射種類別（インターロイキン阻害剤、ヒアルロン酸注射、その他）分析、関節別（膝・足首、股関節、肩・肘、脊椎椎間関節、その他）分析、流通チャネル別（病院薬局、ドラッグストア・薬局、オンライン配給者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Abbvie Inc、Anika Therapeutics、Bioventus、Eli Lilly and Company、Ferring Pharmaceuticals Inc.、PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)、Pfizer Inc.、Sanofi S.A.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の関節痛注射市場規模：注射種類別
- インターロイキン阻害剤の市場規模
- ヒアルロン酸注射の市場規模
- その他の市場規模
・世界の関節痛注射市場規模：関節別
- 膝・足首における市場規模
- 股関節における市場規模
- 肩・肘における市場規模
- 脊椎椎間関節における市場規模
- その他における市場規模
・世界の関節痛注射市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・薬局チャネルの市場規模
- オンライン配給者チャネルの市場規模
・世界の関節痛注射市場規模：地域別
- 北米の関節痛注射市場規模
- ヨーロッパの関節痛注射市場規模
- アジア太平洋の関節痛注射市場規模
- 中南米・中東・アフリカの関節痛注射市場規模
・企業状況
・企業情報

世界の関節痛注射市場は、2021年に62億7,191万ドル、2031年には131億7,631万ドルに達すると予測され、2022年から2031年までの年平均成長率は7.7%となる見込みです。

関節痛の注射は、損傷した関節組織に直接薬剤を塗布する非外科的処置のことを指します。関節痛は、関節炎やそのさまざまな種類、関節の過去の傷害、筋肉の使い過ぎ、うつ病、不安、ストレス、肥満を含むさまざまな理由に関連付けられている関節に引き起こされる不快感として定義されます。さらに、インターロイキン阻害剤は、関節の痛みや炎症を和らげるために、麻酔薬とコルチコステロイドを組み合わせた最も一般的な治療注射の1つです。

関節炎財団によると、2022年現在、関節炎と診断された成人の数は約6000万人で、成人の4人に1人がこれらの関節炎のいずれかを患っています。座りっぱなしのライフスタイル、肥満の増加、運動やストレスによる怪我が原因で、すべての年齢層で関節炎の発生率が増加しているため、大規模な関節痛注射の販売につながるでしょう。
さらに、関節痛注射市場は、製薬会社による最先端の治療技術の導入、患者による正確な治療オプションの需要の増加、先進国における高所得の利用可能性によって成長すると予想されています。

また、関節炎財団は、16歳未満の子供に発症する炎症性疾患とリウマチ性疾患は、若年性関節炎であることが知られており、米国では、30万人近くの子供と10代の若者たちが罹患していると述べています。このように、政府によって提供されるより多くのイニシアチブと資金は、市場の成長を後押しします。

加えて、関節炎の有病率の上昇、肥満や老人患者の増加に伴い、医療インフラを改善する目的で、市場の公的および民間プレーヤーによる高度で正確な治療オプションの研究開発のための投資の増加は、関節痛注射市場の拡大のための主要な要因です。例えば、Skyrizi（risankizumab-rzaa）は、成人の活動性乾癬性関節炎の治療薬として、年4回の単回注射が可能な2つ目の適応症が米国FDAから承認されました。
しかし、発展途上国におけるこれらの注射剤に関する認知度の低さ、高価格、新興国における製品導入に影響を与える償還政策の欠如などの要因により、近い将来、市場は大きな制約を受けると予想されます。しかし、主要な市場プレーヤーは、予測期間中に有利な機会を提供する単回注射療法とプラズママトリックス療法を含む、より効率的な治療オプションを開発しています。

関節痛注射市場は、注射タイプ別、関節タイプ別、流通チャネル別、地域別に区分されます。注射タイプ別では、インターロイキン阻害剤、ヒアルロン酸注射、その他に分類されます。関節タイプ別では、膝・足関節、股関節、肩・肘関節、脊椎ファセット関節、その他に分類されます。流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。さらに、病院薬局セグメントは公立病院薬局と私立病院薬局に分けられます。地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

本レポートに掲載されている主要企業には、Abbvie Inc.、Anika Therapeutics Inc.、Bioventus Inc.、Eli Lilly and Company、Ferring Pharmaceuticals Inc.、Pacira Biosciences (Flexion Therapeutics, Inc.)、Pfizer Inc.、Sanofi S.A.、Teva Pharmaceuticals、Zimmer Biometなどがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの関節痛注射市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、優勢な関節痛注射市場の機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・関節痛注射市場の細分化に関する詳細な分析により、市場機会を特定します。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別、世界の関節痛注射の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
注射剤タイプ別
インターロイキン阻害剤
ヒアルロン酸注射
その他

関節タイプ別
膝関節・足関節
股関節
肩・肘
脊椎ファセット関節
その他

流通チャネル別
病院薬局
ドラッグストア・薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Abbvie Inc
Anika Therapeutics
Bioventus
Eli Lilly and Company
Ferring Pharmaceuticals Inc.
PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
Pfizer Inc.
Sanofi S.A.
Teva Pharmaceuticals
Zimmer Biomet

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Interleukin Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hyaluronic Acid Injections
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Knee and Ankle
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hip Joint
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Shoulder and Elbow
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Facet Joints of the Spine
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Others
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospital Pharmacies Joint Pain Injections Market by Type
6.2.4.1 Public Hospital Pharmacies Market size and forecast, by region
6.2.4.2 Private Hospital Pharmacies Market size and forecast, by region
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Injection Type
7.2.3 North America Market size and forecast, by Joint Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.4.1 North America Hospital Pharmacies Joint Pain Injections Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Injection Type
7.2.5.1.2 Market size and forecast, by Joint Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Injection Type
7.2.5.2.2 Market size and forecast, by Joint Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Injection Type
7.2.5.3.2 Market size and forecast, by Joint Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Injection Type
7.3.3 Europe Market size and forecast, by Joint Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.4.1 Europe Hospital Pharmacies Joint Pain Injections Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Injection Type
7.3.5.1.2 Market size and forecast, by Joint Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Injection Type
7.3.5.2.2 Market size and forecast, by Joint Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Injection Type
7.3.5.3.2 Market size and forecast, by Joint Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Injection Type
7.3.5.4.2 Market size and forecast, by Joint Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Injection Type
7.3.5.5.2 Market size and forecast, by Joint Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Injection Type
7.3.5.6.2 Market size and forecast, by Joint Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Injection Type
7.4.3 Asia-Pacific Market size and forecast, by Joint Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.4.1 Asia-Pacific Hospital Pharmacies Joint Pain Injections Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Injection Type
7.4.5.1.2 Market size and forecast, by Joint Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Injection Type
7.4.5.2.2 Market size and forecast, by Joint Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Injection Type
7.4.5.3.2 Market size and forecast, by Joint Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Injection Type
7.4.5.4.2 Market size and forecast, by Joint Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Injection Type
7.4.5.5.2 Market size and forecast, by Joint Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Injection Type
7.4.5.6.2 Market size and forecast, by Joint Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Injection Type
7.5.3 LAMEA Market size and forecast, by Joint Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.4.1 LAMEA Hospital Pharmacies Joint Pain Injections Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Injection Type
7.5.5.1.2 Market size and forecast, by Joint Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Injection Type
7.5.5.2.2 Market size and forecast, by Joint Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Injection Type
7.5.5.3.2 Market size and forecast, by Joint Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Injection Type
7.5.5.4.2 Market size and forecast, by Joint Type
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbvie Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Anika Therapeutics
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bioventus
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Ferring Pharmaceuticals Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sanofi S.A.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceuticals
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Zimmer Biomet
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 2. JOINT PAIN INJECTIONS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. JOINT PAIN INJECTIONS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. JOINT PAIN INJECTIONS MARKET, FOR HYALURONIC ACID INJECTIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. JOINT PAIN INJECTIONS MARKET FOR HYALURONIC ACID INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 9. JOINT PAIN INJECTIONS MARKET, FOR KNEE AND ANKLE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. JOINT PAIN INJECTIONS MARKET FOR KNEE AND ANKLE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. JOINT PAIN INJECTIONS MARKET, FOR HIP JOINT, BY REGION, 2021-2031 ($MILLION)
TABLE 12. JOINT PAIN INJECTIONS MARKET FOR HIP JOINT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. JOINT PAIN INJECTIONS MARKET, FOR SHOULDER AND ELBOW, BY REGION, 2021-2031 ($MILLION)
TABLE 14. JOINT PAIN INJECTIONS MARKET FOR SHOULDER AND ELBOW, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. JOINT PAIN INJECTIONS MARKET, FOR FACET JOINTS OF THE SPINE, BY REGION, 2021-2031 ($MILLION)
TABLE 16. JOINT PAIN INJECTIONS MARKET FOR FACET JOINTS OF THE SPINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. JOINT PAIN INJECTIONS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. JOINT PAIN INJECTIONS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. GLOBAL HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 23. JOINT PAIN INJECTIONS MARKET, FOR PUBLIC HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 24. JOINT PAIN INJECTIONS MARKET, FOR PRIVATE HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 25. JOINT PAIN INJECTIONS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 26. JOINT PAIN INJECTIONS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. JOINT PAIN INJECTIONS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. JOINT PAIN INJECTIONS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. JOINT PAIN INJECTIONS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 36. U.S. JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 37. U.S. JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 39. CANADA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 40. CANADA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 42. MEXICO JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 43. MEXICO JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 46. EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. EUROPE HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 50. GERMANY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 51. GERMANY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. FRANCE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 53. FRANCE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 54. FRANCE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. UK JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 56. UK JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 57. UK JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. ITALY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 59. ITALY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 60. ITALY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. SPAIN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 62. SPAIN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 63. SPAIN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 73. JAPAN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 74. JAPAN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. CHINA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 76. CHINA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 77. CHINA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. INDIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 82. INDIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 83. INDIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 91. LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 92. LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. LAMEA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. LAMEA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 96. BRAZIL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 97. BRAZIL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 107.ABBVIE INC: COMPANY SNAPSHOT
TABLE 108.ABBVIE INC: OPERATING SEGMENTS
TABLE 109.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 110.ABBVIE INC: NET SALES,
TABLE 111.ABBVIE INC: KEY STRATERGIES
TABLE 112.ANIKA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 113.ANIKA THERAPEUTICS: OPERATING SEGMENTS
TABLE 114.ANIKA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 115.ANIKA THERAPEUTICS: NET SALES,
TABLE 116.ANIKA THERAPEUTICS: KEY STRATERGIES
TABLE 117.BIOVENTUS: COMPANY SNAPSHOT
TABLE 118.BIOVENTUS: OPERATING SEGMENTS
TABLE 119.BIOVENTUS: PRODUCT PORTFOLIO
TABLE 120.BIOVENTUS: NET SALES,
TABLE 121.BIOVENTUS: KEY STRATERGIES
TABLE 122.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 123.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 124.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 125.ELI LILLY AND COMPANY: NET SALES,
TABLE 126.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 127.FERRING PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 128.FERRING PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 129.FERRING PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 130.FERRING PHARMACEUTICALS INC.: NET SALES,
TABLE 131.FERRING PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 132.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): COMPANY SNAPSHOT
TABLE 133.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): OPERATING SEGMENTS
TABLE 134.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): PRODUCT PORTFOLIO
TABLE 135.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): NET SALES,
TABLE 136.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): KEY STRATERGIES
TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
TABLE 138.PFIZER INC.: OPERATING SEGMENTS
TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 140.PFIZER INC.: NET SALES,
TABLE 141.PFIZER INC.: KEY STRATERGIES
TABLE 142.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 143.SANOFI S.A.: OPERATING SEGMENTS
TABLE 144.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 145.SANOFI S.A.: NET SALES,
TABLE 146.SANOFI S.A.: KEY STRATERGIES
TABLE 147.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 148.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 149.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 150.TEVA PHARMACEUTICALS: NET SALES,
TABLE 151.TEVA PHARMACEUTICALS: KEY STRATERGIES
TABLE 152.ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 153.ZIMMER BIOMET: OPERATING SEGMENTS
TABLE 154.ZIMMER BIOMET: PRODUCT PORTFOLIO
TABLE 155.ZIMMER BIOMET: NET SALES,
TABLE 156.ZIMMER BIOMET: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 乾癬治療のグローバル市場（2021〜2031）：TNF-α阻害剤、インターロイキン阻害剤、その他
  • 世界の乾癬性関節炎治療薬市場2022年ｰ2031年：薬効クラス別（TNF阻害剤、インターロイキン阻害剤、PDE4阻害剤、その他）、投与経路別
  • 関節内補充治療のグローバル市場（2021〜2031）：注射1回による関節内補充治療、注射3回による関節内補充治療、注射5回による関節内補充治療
  • 目地材のグローバル市場（2021～2031）：ポリウレタン製目地材、シリコーン製目地材、ポリサルファイド製目地材、熱間注入型目地材、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB180 )"関節痛注射のグローバル市場（2021〜2031）：インターロイキン阻害剤、ヒアルロン酸注射、その他" (英文：Joint Pain Injections Market By Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections, Others), By Joint Type (Knee and Ankle, Hip Joint, Shoulder and Elbow, Facet Joints of the Spine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。